Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

计划入组 24 人 · 首次发布于 2025 年 11 月 20 日

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

计划入组 52 人 · 首次发布于 2021 年 6 月 28 日

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis

计划入组 12 人 · 首次发布于 2024 年 12 月 27 日

NTR-452

NTR-101

NTR-441

UNIVERSITY OF MINNESOTA

United States

ETR ASSOCIATES

United States

NTC SRL

Italy

Neutrolis Reports Positive Phase 1a Results for First-in-Class NET-Targeting Therapy NTR-1011

Neutrolis to Present Early Human Proof-of-Concept Data for Novel NET-Targeting Therapy at ACR 2025

Breakthrough Therapies Set to Transform Eosinophilic Esophagitis Treatment Landscape